Object. Individually, the cytokines erythropoietin (EPO) and insulin-like growth factor-I (IGF-I) have both been shown to reduce neuronal damage significantly in rodent models of cerebral ischemia. The authors have previously shown that EPO and IGF-I, when administered together, provide acute and prolonged neuroprotection in cerebrocortical cultures against N-methyl-d-aspartate-induced apoptosis. The aim of this study was to determine whether intranasally applied EPO plus IGF-I can provide acute neuroprotection in an animal stroke model and to show that intranasal administration is more efficient at delivering EPO plus IGF-I to the brain when compared with intravenous, subcutaneous, or intraperitoneal administration.
S
troke is the third most common cause of death in the US after heart disease and all cancer, and is a major contributor to severe disability. As the most common cause of neurological disability, ischemic stroke is often associated with sensorimotor and cognitive impairments due to neuronal degeneration. Intravenous administration of recombinant tissue plasminogen activator is the only FDA-approved medical therapy for treatment of patients with acute ischemic stroke, but recombinant tissue plasminogen activator can only be given within 3 hours of symptom onset, and only 2% of patients are eligible. 1 A number of studies are being conducted to find neuroprotective agents that can improve the outcome and provide a larger window of opportunity for stroke patients. However, the delivery of a wide range of possible therapeutic agents to the brain is hampered by the BBB. Intranasal drug administration could offer a noninvasive method that circumvents the BBB and provides rapid drug absorption for acute brain insults without systemic side effects. 11 A number of different growth factors, pepIntranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke I-EPO and 125 I-IGF-I into the mouse brain after intranasal, intravenous, subcutaneous, or intraperitoneal administration.
Results. Intranasal administration of EPO plus IGF-I reduced stroke volumes within 24 hours and improved neurological function in mice up to 90 days after MCAO. The 125 I-EPO and 125 I-IGF-I were found in the brain within 20 minutes after intranasal administration and accumulated within the injured areas of the brain. In addition, intranasal administration delivered significantly higher levels of the applied 125 I-EPO and 125 I-IGF-I to the brain compared with intravenous, subcutaneous, or intraperitoneal administration.
Conclusions. The data demonstrate that intranasal EPO plus IGF-I penetrates into the brain more efficiently than other drug delivery methods and could potentially provide a fast and efficient treatment to prevent chronic effects of stroke. (DOI: 10.3171/2009.2.JNS081199) tides, and hormones have been reported to enter the brain and CSF through the olfactory epithelium and to promote neurogenesis, 12 inhibit neurodegeneration, 6 ,21 improve neurological function, 2, 10, 24 and protect against cerebral ischemia. 16, 17, [27] [28] [29] Erythropoietin has been identified as a neurotrophic and neuroprotective agent in many different animal models of brain injury. 19 Originally identified as a hematopoietic factor, EPO and its receptor are expressed in the mammalian CNS. 8 Brain-derived EPO is upregulated by hypoxia, 3, 8, 18 and expression of both EPO and its receptor are specifically modulated during cerebral ischemia. 4, 23 The EPO molecule is an extremely well-studied and well-tolerated compound in humans, and its use in stroke patients has been promising, at least in some studies.
We have previously shown that the efficacy of EPO is increased when combined with IGF-I in an in vitro model. 9 When EPO and IGF-I are given together, they provide acute and prolonged neuroprotection by synergistically activating the phosphoinositide 3-kinase/protein kinase B pathway, thereby preventing apoptosis. We investigate the effects of intranasal administration of EPO plus IGF-I on long-term behavioral outcome in a mouse model for transient ischemia. In addition, we compare intranasal administration to intravenous, subcutaneous, or intraperitoneal administration. Our results indicate that intranasal application of EPO plus IGF-I could provide a novel, noninvasive method for acute neuroprotection after stroke.
Methods

Transient MCAO
All animal experiments were approved by the Institutional Animal Care and Use Committee of The University of Texas Health Science Center at San Antonio. Adult male C57Bl/6 mice weighing between 20 and 25 g were used for the present study. Mice were anesthetized with 1.5-2% isoflurane in a mixture of 70% nitrous oxide and 30% oxygen. The animals' body temperatures were maintained at 37°C with a heating blanket and feedback system (Harvard Apparatus). Transient focal cerebral ischemia was induced by occlusion of the left MCA by using the intraluminal filament model. 15 Reperfusion was performed by withdrawal of the filament 1 hour after occlusion. Cytokines were administered immediately after withdrawal of the filament. Surface cerebral blood flow was monitored during MCAO by using a laser Doppler flowmeter (Perimed). Mice with surface cerebral blood flow > 20% of baseline were deemed to have unsuccessful occlusions of the MCA and were excluded from the experiment.
Intranasal Administration
A recently described method for intranasal application was used, with slight modifications for mice. 
Evaluation of Cerebral Infarction
Mice subjected to 1-hour MCAO received intranasal EPO (100 U), IGF-I (1000 ng), EPO plus IGF-I (100 U plus 1000 ng), or vehicle (16 animals per group). After 24 hours of reperfusion, an observer blinded to the identity of the groups assessed neurological behavior and scored the results as follows: 0, no observable neurological deficit (normal); 1, failure to extend left forepaw upon suspension by tail (mild); 2, circling to the contralateral side (moderate); and 3, leaning to the contralateral side at rest or no spontaneous motor activity (severe). The mice were killed using isoflurane, and their brains were sectioned coronally at 1-mm intervals. The brain sections were incubated in a 2% solution of TTC at 37°C for 5 minutes and fixed by immersion in 4% paraformaldehyde. The area of infarction was measured digitally with the National Institutes of Health 1.62 imaging system. The volume of infarction was calculated by numerical integration of sequential areas, and expressed as a percentage of wholebrain volume after correction for edema, as we have described previously. 15 Differences in stroke volumes were analyzed by ANOVA, followed by a post hoc Scheffé test for multiple comparisons (p < 0.05 was taken as statistically significant).
Liquid Scintillation
Mice received intranasal 125 I-EPO (100 U) and 125 I-IGF-I (1000 ng) as described above. After 20 or 60 minutes, whole brains (without the olfactory bulb) from untreated and treated mice were collected and homogenized in 1 ml buffer (50 mM Tris-HCl, pH 7.4). Samples were then prepared for liquid scintillation measurement (Perkin Elmer) after the addition of scintillation fluid. To exclude blood contamination, dpm levels from blood samples were subtracted from the total brain values. Differences in dpm levels were analyzed using 1-way ANOVA, keeping significance at a probability < 0.05.
To compare different drug delivery methods, control mice and animals subjected to MCAO received intranasal 125 I-EPO (100 U), intranasal 125 I-IGF-I (1000 ng), or subcutaneous, intravenous, or intraperitoneal injections each of 125 I-EPO (5000 U/kg) or 125 I-IGF-I (50 µg/kg). Mice subjected to MCAO received 125 I-EPO or 125 I-IGF-I after removal of the suture. The brains were collected at various time points (10-720 minutes) following drug administration and prepared for liquid scintillation measurement as described above. The mean dpm values were used to calculate EPO (in units) and IGF-I (in nanograms) concentrations. The Kruskal-Wallis test was used to compare concentrations between the different delivery methods for EPO and IGF-I in normal and poststroke brains, keeping significance at a probability < 0.05. Further post hoc comparisons between the different delivery methods for EPO and IGF-I for different time points in normal and poststroke brain were performed using the Mann-Whitney test, keeping significance at a probability < 0.003 (after the Bonferroni correction).
Autoradiography Studies
Mice subjected to MCAO received intranasal 125 I-EPO (100 U) and 125 I-IGF-I (1000 ng). Brains were removed 24 hours after MCAO, frozen in liquid nitrogen-cooled isopentane, and embedded in TissueTek 4583 CRYO-OCT Compound (Sakura Finetek). Embedded brains were sectioned into 20-µm sections and transferred onto gelatincoated coverslips. Brain sections were exposed to x-ray film for 2-4 days. Sections that were used for autoradiography were stained with cresyl violet for neuronal morphological studies and correlated to the respective autoradiography pattern to identify the morphological location of the radiolabeled cytokines.
Behavioral Tests
All behavioral testing was modeled after a previously described method 7 that was modified for this project. Randomly selected mice were grouped as follows (8 per group): Group I animals were subjected to MCAO and treated with vehicle; Group II animals were subjected to MCAO and treated with EPO (100 U); Group III animals were subjected to MCAO and treated with IGF-I (500 ng); and Group IV animals were subjected to MCAO and treated with EPO plus IGF-I (100 U plus 500 ng). An observer blinded to the identity of the groups assessed neurological behavior at 3, 30, 60, and 90 days. Three trials were performed for each behavioral test on each testing day for each mouse. The scores were analyzed using 1-way ANOVA, and post hoc Newman-Keuls tests were used to compare the differences among the treatment groups. To analyze day-by-day differences, repeated-measures ANOVA was performed, followed by the Bonferroni test for multiple comparisons. A probability value < 0.05 was considered significant.
Sticky Label Test (Modified Schallert Tape Test).
Each mouse was picked up by the scruff of the neck and the tail was fixed between fingers and palm. A cuff of tape measuring 4 × 0.5 cm was placed over the right paw and pressed to attach to the front and back of the paw. The mouse was released into an empty clear plastic box and timed until the tape from its paw was removed by any means (mouth, other paw, and so on). It has been reported that spontaneous recovery in mice has very little effect on the sticky label test. 7 Open Field Test. Individual mice were tested in 1 trial at specific intervals before and after stroke induction surgery. Mice were placed in a white Plexiglas box under lighting to avoid any shadows or irregular lighting. On the bottom of the 0.6 × 0.6-m box is a grid pattern of boxes roughly 10 cm 2 . Mice were released from the center of the pattern, and the number of boxes they entered was counted for 90 seconds. If a mouse put all 4 paws in 1 box, it was counted as a movement. Effects of spontaneous recovery following MCAO on the open field test have not been reported. Figure 1 shows that whole-brain lysates collected only 20 minutes after intranasal application had significantly higher levels in the brain compared with controls (p < 0.01). The levels of 125 I-EPO and 125 I-IGF-I were still increasing after 60 minutes and were significantly higher when compared with levels at 20 minutes (p < 0.01).
Results
Levels
Intranasal EPO Plus IGF-I Reduces Infarct Volume After MCAO
Mice subjected to MCAO received intranasal EPO, IGF-I, EPO plus IGF-I, or vehicle at the start of reperfusion. Infarct volumes were measured 24 hours later and are shown in Fig. 2 . Analysis of stroke damage indicates that EPO plus IGF-I reduced infarct volumes more than either cytokine alone. To assess the beneficial effect of intranasal EPO plus IGF-I on neurological outcome, the mice were scored according to the severity of the neurological deficit. The results shown in Table 1 demonstrate that mice treated with EPO plus IGF-I after MCAO had fewer neurological deficits than those treated with either EPO or IGF-I alone. 125 I-IGF-I (1000 ng), or a combination of the two, and were killed at 20 minutes (white bars) or 60 minutes (black bars). The presence of radiolabeled EPO and IGF-I in whole-brain lysates was then measured in a scintillation counter. To exclude blood contamination, dpm levels from blood samples were subtracted from the total brain values. The mean dpm and SD are plotted for 3 mice in each group. *p < 0.01 for treated versus control; †p < 0.01 for level at 20 minutes versus 60 minutes.
To determine whether EPO and IGF-I can reach the injured areas of the brain after stroke, mice that underwent MCAO received intranasal 125 EPO, 125 IGF-I, or a combination of these substances after withdrawal of the filament. The brains were removed 20 minutes after intranasal administration. Exogenous 125 I-EPO and 125 I-IGF-I detected by autoradiography resulted in a darker signal in the areas of infarction compared with the rest of the uninjured brain (Fig. 3) , indicating an accumulation of the radiolabeled cytokines in the stroke core and penumbra.
Sticky Label Test
To test for somatosensory deficiencies, the mice in each group were timed to see how long it would take them to remove a piece of tape from their affected forepaw following MCAO. The mice that received intranasal EPO, IGF-I, or EPO plus IGF-I were able to perform the task significantly faster than the vehicle-treated mice on Days 3, 30, 60, and 90 (Fig. 4 , p < 0.05). The EPO plus IGF-Itreated mice performed the task significantly faster than the animals treated with EPO or IGF-I alone on all 4 testing days (p < 0.01). The EPO plus IGF-I-treated mice also showed significant improvement from Day 3 to Day 30 (p < 0.01). After 90 days post-MCAO, the vehicletreated mice took > 6 minutes to complete the task, and the EPO-or IGF-I-treated groups needed between 2 and 3 minutes. All of the EPO plus IGF-I-treated mice were able to complete the task in < 1 minute by 60 or 90 days post-MCAO.
Open Field Test
To test the locomotor activity of the mice in each group, an open field test was used. The mice that received intranasal EPO, IGF-I, or EPO plus IGF-I entered more squares than the vehicle-treated mice on Days 3, 30, 60, and 90 (Fig. 4 , p < 0.01). The EPO plus IGF-I-treated mice performed the task significantly better than the EPO-treated mice on all 4 testing days, and animals in this group were better than the IGF-I-treated mice on Days 3, 60, and 90 (p < 0.01). The EPO plus IGF-I-treated mice did not show any improvement from Days 3 to 30, but the group did show significant improvement from Days 30 to 60 (p < 0.01).
Comparison of Intranasal Administration to Other Drug Delivery Methods
To determine which drug delivery method is able to deliver higher levels of EPO and IGF-I to the brain, mice Table 1 . received intranasal 125 I-EPO (100 U) or 125 I-IGF-I (1000 ng), and were compared with mice that received intravenous, intraperitoneal, or subcutaneous injections of 125 I-EPO (5000 U/kg) or 125 I-IGF-I (50 µg/kg). In addition, mice that underwent 1 hour of MCAO also received the same treatments. Intranasal delivery showed the highest concentrations and earliest peak concentrations compared with subcutaneous, intravenous, and intraperitoneal injections (Fig. 5) . Intranasal 125 I-EPO and 125 I-IGF-I concentrations peaked at 60-120 minutes versus 240-360 minutes for the other delivery systems. The superiority of intranasal delivery was seen for both 125 I-EPO and 125 I-IGF-I and for normal and poststroke brain (p < 0.01). In the normal brain, intranasal 125 I-EPO reached a maximum of 20 U after only 20 minutes (Fig. 5A) , and intranasal 125 I-IGF-I reached a maximum of 45 ng after 60 minutes (Fig. 5B) . In the brain poststroke, intranasal 125 I-EPO reached a maximum of 33 U by 120 minutes (Fig. 5C) , and intranasal 125 I-IGF-I reached a maximum of 54 ng after 60 minutes (Fig. 5D) . In contrast, the maximum concentration of 125 I-EPO given intravenously, intraperitoneally, or subcutaneously only reached 1 U in the normal brain (Fig. 5A ) and 3.5 U in the poststroke brain (Fig. 5C ). The maximum concentration of 125 I-IGF-I given intravenously, intraperitoneally, or subcutaneously only reached 3.5 ng in the normal brain (Fig.  5B) , and 4.5 ng in the brain after stroke (Fig. 5D ).
Discussion
The therapeutic potential of systemically applied EPO and IGF-I is limited by their poor ability to cross the BBB, thus limiting their availability in the brain. It has been reported that large doses of EPO administered systemically will enter the CSF through the brain capillary endothelial cells by receptor-mediated endocytosis. 5, 14 However, the need for very high dosages to achieve neuroprotection can potentially lead to elevated hematocrit levels, increased blood viscosity, and perfusion deficits in the brain. 26 The IGF-I cytokine also has difficulty crossing the BBB, except at specific hypothalamic and anterior thalamic nuclei. 22 In addition, systemically applied IGF-I can be sequestered by IGF-binding proteins, which bind IGF-I with an affinity equal to or greater than that of the IGF-I receptor, 13, 20 thereby limiting the amount of IGF-I that can penetrate into the brain.
Increasing interest has been expressed in the possibility of circumventing the BBB by delivering peptidyl drugs to the CNS through the intranasal pathway. This pathway is believed to involve 2 general mechanisms. 11 The first is internalization of the drug into the primary neurons of the olfactory epithelium, either by endocytotic or pinocytotic mechanisms, and intracellular axonal transport to the olfactory bulb. The second is an extracellular pathway that allows for rapid absorption of the drug across the olfactory epithelial cells, either by transcellular or paracellular mechanisms, followed by uptake into the CNS.
In the present study, we demonstrate that 125 I-IGF-I (as described by others 16, 17, 25 ) and 125 I-EPO can gain entry into the CNS within 20 minutes following intranasal application. The rate at which 125 I-EPO and 125 I-IGF-I appear in the brain suggests an extracellular route across olfactory epithelial cells. It is possible that EPO could also be transported along the trigeminal pathway, as described recently for IGF-I. 25 We measured similar dpm levels in the brains for 125 I-EPO and 125 I-IGF-I at 20 and 60 minutes after intranasal application. However, when given together, 125 I-EPO plus 125 I-IGF-I did not have a cumulative effect on dpm levels. This suggests that 125 I-EPO and 125 I-IGF-I are being taken up by a similar yet unknown mechanism. Further studies will be needed to elucidate the exact uptake mechanism. We also observed that intranasal 125 I-EPO and 125 I-IGF-I accumulated within the injured areas of the brain after MCAO, which suggests that this application method enables the cytokines to target the ischemic brain tissue.
We had shown previously that EPO plus IGF-I protects neurons in culture against apoptosis-inducing excitotoxic insults to a greater degree than either cytokine alone. 9 Therefore, we hypothesized that EPO plus IGF-I may also be capable of preventing damage after cerebral ischemia/ reperfusion injury in vivo. The present study shows that intranasal administration of EPO plus IGF-I reduces stroke damage in mice more efficiently than either cytokine alone. We demonstrate that EPO plus IGF-I can decrease stroke volumes and improve neurological function within 24 hours. Interestingly, we found that a single dosing of intranasal EPO plus IGF-I applied at the beginning of the reperfusion is sufficient to improve neurological outcomes in mice 90 days post-MCAO. Further studies will supply information on whether long-term treatment with multiple intranasal applications of EPO plus IGF-I will provide even further improvement after stroke. Moreover, the possibility that intranasal application of EPO plus IGF-I would expand the treatment window if administered several hours after reperfusion needs to be explored.
The intranasal delivery method was significantly more efficient at delivering 125 I-EPO and 125 I-IGF-I to the normal and poststroke brain than the other standard delivery systems evaluated in this study. Intranasal delivery achieved peak brain tissue concentrations 7-31 times higher for 125 I-EPO and 12-20 times higher for 125 I-IGF-I, and at an earlier time interval than the other delivery methods. The peak concentrations for all delivery methods were higher in the poststroke brain than in the normal brain, most likely due to increased BBB permeability from ischemia-induced vascular dysfunction. It was also seen that 125 I-EPO and 125 I-IGF-I concentrations remained high for a longer period in the poststroke brain than in the normal brain, most likely because of vascular dysfunction and impairment of the peptide transport mechanisms from the interstitial to the intravascular space.
Conclusions
Stroke is the most common cause of neurological disability in the US. Current treatment options for hyperacute and acute stroke are limited, and specific long-term neuroprotective and neurorestorative treatments have not been established. The present study demonstrates a cooperative neuroprotective effect of EPO plus IGF-I in vivo. Our findings suggest that the coadministration of these neuroprotective agents, rather than delivery of a single agent, may provide greater benefit for the acute treatment of patients suffering from stroke. In addition, the intranasal pathway provides a noninvasive method that further enhances the efficiency of EPO and IGF-I by lowering the dosage needed and providing a faster delivery route to the brain. The EPO cytokine is already widely used for the treatment of anemia, and IGF-I has a proven safety record in advanced clinical trials. Thus, treatment with intranasal EPO plus IGF-I could provide a novel therapeutic strategy for a variety of acute neurological events, including stroke.
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